A possible explanation for this might be found in a study of 198 breast cancers, showing that overexpression of EGFR led to a significantly better response to neoadjuvant chemotherapy and was significantly associated with a higher rate of pathological complete responses. The gene discussed is EGFR; the disease is breast carcinoma.